Search by Drug Name or NDC
NDC 25021-0312-04 Verapamil Hydrochloride 2.5 mg/mL Details
Verapamil Hydrochloride 2.5 mg/mL
Verapamil Hydrochloride is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sagent Pharmaceuticals. The primary component is VERAPAMIL HYDROCHLORIDE.
Product Information
| NDC | 25021-0312 |
|---|---|
| Product ID | 25021-312_b4eb5dd2-5e25-4ecc-ac57-8897f2b6984a |
| Associated GPIs | 34000030102005 |
| GCN Sequence Number | 000563 |
| GCN Sequence Number Description | verapamil HCl VIAL 2.5 MG/ML INTRAVEN |
| HIC3 | A9A |
| HIC3 Description | CALCIUM CHANNEL BLOCKING AGENTS |
| GCN | 01650 |
| HICL Sequence Number | 000180 |
| HICL Sequence Number Description | VERAPAMIL HCL |
| Brand/Generic | Generic |
| Proprietary Name | Verapamil Hydrochloride |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Verapamil Hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 2.5 |
| Active Ingredient Units | mg/mL |
| Substance Name | VERAPAMIL HYDROCHLORIDE |
| Labeler Name | Sagent Pharmaceuticals |
| Pharmaceutical Class | Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA214361 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 25021-0312-04 (25021031204)
| NDC Package Code | 25021-312-04 |
|---|---|
| Billing NDC | 25021031204 |
| Package | 5 VIAL in 1 CARTON (25021-312-04) / 4 mL in 1 VIAL |
| Marketing Start Date | 2021-03-15 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |